Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication (Q88884600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

title

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

10

Carl H June

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

6

Simon F Lacey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Christopher C Kloss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jihyun Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Aaron Zhang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Fang Chen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jan Joseph Melenhorst

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Marcela V Maus

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Joseph A Fraietta

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Yangbing Zhao

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

publication date

8 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

page(s)

1855-1866

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

The Diagnosis and Treatment of Prostate Cancer: A Review

28 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Elements of cancer immunity and the cancer-immune set point

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Neoantigen landscape dynamics during human melanoma-T cell interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Is autoimmunity the Achilles' heel of cancer immunotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Therapeutic T cell engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

The Principles of Engineering Immune Cells to Treat Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Immunosuppressive strategies that are mediated by tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

T cell exclusion, immune privilege, and the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

TGF-β activation and function in immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

STRING v10: protein-protein interaction networks, integrated over the tree of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

The central role of CD4(+) T cells in the antitumor immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Current status of chimeric antigen receptor therapy for haematological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Power and sample size calculations for studies involving linear regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2018.05.003

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29807781

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2018.05.003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29807781%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference